Quality and Vigilance in a Post-Brexit Regulatory Environment
Brexit has reshaped the UK’s pharmaceutical landscape, and by 2025 the country now operates a fully independent regulatory framework for medicines. Under the updated arrangements introduced through the Windsor Framework, the Medicines and Healthcare products Regulatory Agency (MHRA) manages every aspect of product licensing, safety monitoring, and quality oversight across the entire United Kingdom.
This shift means that the UK no longer follows a split system between Great Britain and Northern Ireland. Instead, companies now work under one unified regulatory structure, bringing both simplifications and new responsibilities. The major areas affected include licensing routes, packaging and labelling requirements, quality management expectations, and pharmacovigilance processes.
The Changing Regulatory Landscape in 2025
By 2025, the UK’s regulatory environment has fully transitioned into a UK-centric model. While this move reduces some complications, it also requires companies to update internal systems, reassess compliance frameworks, and maintain dual operations if they supply both UK and EU markets.
Key areas of change include:
- UK-wide marketing authorisations
- Mandatory UK Only packaging and labelling
- Updated pharmacovigilance expectations
- Divergence from EU requirements
- Revised processes for medical devices and combination products
These changes have direct implications for Quality, Regulatory Affairs, Pharmacovigilance, Manufacturing, and Supply Chain teams.
1. UK-Wide Marketing Authorisations
A major shift in 2025 is the introduction of a single licensing route for the entire United Kingdom. Companies no longer need separate authorisations for GB and Northern Ireland, which simplifies some regulatory tasks but centralises responsibility under one approval.
What this means for companies:
- One submission route to MHRA for the entire UK
- Removal of the previous GB/NI split for licensing
- Clearer oversight of product lifecycle management
- More centralised decision-making on quality and safety
Quality & Vigilance Impact
- Streamlined submissions with fewer regional variations
- More unified quality management expectations
- Higher accountability for uniform batch release
- Simplified change control, but stronger oversight requirements
2. New Packaging and Labelling Requirements
From 2025 onwards, all medicines distributed in the UK must carry a UK Only label. This requirement ensures clear segregation between UK and EU supply chains and prevents accidental cross-market distribution.
Operational expectations include:
- Updating packaging artwork and barcoding
- Revalidating labelling equipment
- Revising SOPs and training relevant teams
- Ensuring accurate segregation between EU and UK production lines
Key considerations for Quality Teams
- Updated artwork and barcoding requirements
- Stricter QA checks for labelling accuracy
- Clear segregation of UK/EU workflows
- Documented controls for packaging and artwork changes
These updates also influence warehouse operations, distribution planning, and release procedures.
3. UK-Centric Pharmacovigilance Reporting
In 2025, pharmacovigilance becomes fully governed by MHRA-led systems, with updated guidance and stricter reporting timelines.
Requirements for companies include:
- Maintaining a UK-compliant Pharmacovigilance System Master File (PSMF)
- Timely reporting of serious and non-serious adverse reactions
- Updated signal detection processes
- Clear separation of UK and EU safety data when necessary
- Ensuring data integrity across multiple safety systems
With increased regulatory divergence, companies working across both markets must maintain dual reporting systems, raising the importance of strong PV governance and documentation.
4. Regulatory Divergence and Operational Complexity
Brexit has resulted in growing differences between the UK and the EU in several areas:
- Serialisation requirements
- Post-market surveillance
- Labelling and packaging conventions
- Safety reporting timelines
- Quality expectations and inspection focus
Impact on internal operations:
- Need to maintain two separate compliance frameworks
- Higher risk of errors due to dual processes
- More detailed document control and process validation
- Stronger cross-functional collaboration between Quality, PV, Regulatory, and Supply Chain
Change control becomes more complex: every modification to manufacturing, packaging, formulation, or safety information must be evaluated for both regulatory systems.
5. Impact on Supply Chain, Quality Systems, and Risk Management
The introduction of UK Only labelling and a unified licensing system changes how companies manage their supply chains.
Effects on supply chain management:
- Segregation between UK and EU markets
- Revised batch release procedures
- Updated warehouse and distribution workflows
- Stronger traceability and documentation requirements
Effects on Quality Management Systems (QMS):
- Revision of SOPs, training materials, and validation documentation
- Updating artwork control and labelling workflows
- Strengthened risk management and error-prevention processes
- More frequent internal audits for UK-specific compliance
Companies must evaluate risks related to mislabelling, cross-market mix-ups, PV reporting delays, and data integrity issues.
6. Changes for Medical Devices and Combination Products
In 2025, the UK also implements updated expectations for medical devices, affecting:
- Post-market surveillance
- Safety reporting
- Device quality system documentation
- Incident reporting timelines
Manufacturers of combination products must align both drug and device reporting systems to ensure consistency and compliance. Companies that update early benefit from MHRA innovation pathways and faster review routes.
What This Means for Quality and Vigilance Stakeholders
Quality Teams Must:
- Update QMS documentation and SOPs
- Validate new packaging and labelling workflows
- Strengthen supply chain oversight
- Reassess risk management processes
- Conduct internal audits for UK-compliance readiness
Vigilance Teams Must:
- Align with MHRA pharmacovigilance reporting requirements
- Update PSMFs, safety procedures, and signal detection systems
- Ensure dual reporting integrity (UK and EU)
- Maintain documentation that meets MHRA inspection expectations
This requires strong collaboration across Quality, PV, Regulatory Affairs, Supply Chain, Packaging, and Manufacturing teams.
Positioning for Long-Term Compliance and Stability
The regulatory changes introduced in 2025 mark a new phase in the UK’s independent regulatory identity. Companies must now operate with a UK-first regulatory approach, ensuring that quality systems, vigilance processes, and supply-chain controls reflect the updated requirements.
Those that strengthen their internal systems, invest in training, and adopt proactive quality governance will be better prepared for future MHRA expectations, patient safety demands, and operational challenges. Robust Quality and Vigilance practices are now essential for sustainability in a post-Brexit environment.
How Q&V Can Help
At Q&V, we understand that strong Quality and Pharmacovigilance systems are essential in today’s evolving UK regulatory landscape. Our experienced auditors and consultants support organisations by:
- Conducting independent GMP/GDP and PV audits to assess compliance.
- Reviewing QMS, documentation, and safety workflows to identify gaps.
- Supporting PV operations including case processing, literature monitoring, and signal management.
- Offering training to strengthen internal quality and vigilance competencies.
We help ensure your systems remain compliant, resilient, and aligned with UK-specific expectations, protecting patients and supporting long-term operational stability.
Get in touch with Quality & Vigilance to learn how our audit and compliance services can support your organisation.